NO20033155D0 - Fremgangsmate for hormonerstatningsterapi og dens administreringsform - Google Patents

Fremgangsmate for hormonerstatningsterapi og dens administreringsform

Info

Publication number
NO20033155D0
NO20033155D0 NO20033155A NO20033155A NO20033155D0 NO 20033155 D0 NO20033155 D0 NO 20033155D0 NO 20033155 A NO20033155 A NO 20033155A NO 20033155 A NO20033155 A NO 20033155A NO 20033155 D0 NO20033155 D0 NO 20033155D0
Authority
NO
Norway
Prior art keywords
administration
replacement therapy
hormone replacement
hormone
therapy
Prior art date
Application number
NO20033155A
Other languages
English (en)
Other versions
NO20033155L (no
Inventor
Hermann Kulmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20033155D0 publication Critical patent/NO20033155D0/no
Publication of NO20033155L publication Critical patent/NO20033155L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20033155A 2001-01-11 2003-07-10 Fremgangsmåte for hormonerstatningsterapi og dens administreringsform NO20033155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10100911A DE10100911A1 (de) 2001-01-11 2001-01-11 Verfahren zur Hormonersatztherapie und dessen Darreichungsform
PCT/EP2002/000089 WO2002055086A2 (en) 2001-01-11 2002-01-08 Hormone replacement therapy method and its administration form

Publications (2)

Publication Number Publication Date
NO20033155D0 true NO20033155D0 (no) 2003-07-10
NO20033155L NO20033155L (no) 2003-09-10

Family

ID=7670195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033155A NO20033155L (no) 2001-01-11 2003-07-10 Fremgangsmåte for hormonerstatningsterapi og dens administreringsform

Country Status (21)

Country Link
US (1) US7871994B2 (no)
EP (1) EP1372665B1 (no)
JP (1) JP2004525883A (no)
AR (1) AR033413A1 (no)
AT (1) ATE348620T1 (no)
AU (1) AU2007202118A1 (no)
BR (1) BR0206361A (no)
CA (1) CA2433656A1 (no)
CY (1) CY1106374T1 (no)
DE (2) DE10100911A1 (no)
DK (1) DK1372665T3 (no)
ES (1) ES2278896T3 (no)
IL (1) IL156655A0 (no)
MX (1) MXPA03006157A (no)
NO (1) NO20033155L (no)
NZ (1) NZ539581A (no)
PE (1) PE20020795A1 (no)
PT (1) PT1372665E (no)
UY (1) UY27117A1 (no)
WO (1) WO2002055086A2 (no)
ZA (1) ZA200306120B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2495330A1 (en) * 2002-08-28 2004-03-11 Robert Casper Estrogen replacement regimen
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
PT1558265E (pt) * 2002-11-05 2010-03-22 Bayer Schering Pharma Ag Utilização da drospirenona para o tratamento da hipertensão
ES2482104T3 (es) 2003-09-29 2014-08-01 Novo Nordisk Femcare Ag Formulaciones HRT
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DE4224534A1 (de) 1992-07-24 1994-01-27 Marika Dr Med Ehrlich Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE4405590C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonbehandlung
DE4405591C1 (de) 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Mittel zur postmenopausalen Hormonsubstitution
DE19513662A1 (de) 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19539233A1 (de) 1995-10-21 1997-04-24 Klaus Dr Med Umbreit Oral einzunehmendes ovulationshemmendes Mittel

Also Published As

Publication number Publication date
CA2433656A1 (en) 2002-07-18
BR0206361A (pt) 2004-02-17
IL156655A0 (en) 2004-01-04
DE10100911A1 (de) 2002-08-01
PT1372665E (pt) 2007-03-30
DE60216899D1 (de) 2007-02-01
AR033413A1 (es) 2003-12-17
NZ539581A (en) 2007-07-27
MXPA03006157A (es) 2003-09-16
CY1106374T1 (el) 2011-10-12
DK1372665T3 (da) 2007-04-30
UY27117A1 (es) 2002-07-31
EP1372665B1 (en) 2006-12-20
ZA200306120B (en) 2004-09-08
EP1372665A2 (en) 2004-01-02
ATE348620T1 (de) 2007-01-15
WO2002055086A2 (en) 2002-07-18
DE60216899T2 (de) 2007-10-25
AU2007202118A1 (en) 2007-05-31
NO20033155L (no) 2003-09-10
US20040106586A1 (en) 2004-06-03
US7871994B2 (en) 2011-01-18
WO2002055086A3 (en) 2003-10-16
JP2004525883A (ja) 2004-08-26
ES2278896T3 (es) 2007-08-16
PE20020795A1 (es) 2002-10-03

Similar Documents

Publication Publication Date Title
FI20012017A (fi) Menetelmä ja laite magneettistimulaation annoslaskentaa varten
EP1414452A4 (en) NEW DOSAGE FORMS BASED ON SUBSTITUTED BENZIMIDAZOLE AND METHOD OF USE THEREOF
EP1551292A4 (en) METHOD FOR ENHANCED CONVECTION DISTRIBUTION OF THERAPEUTIC AGENTS
NO20042993L (no) Formulering og doseringsform for kontrollert levering av terapeutiske midler
NO20050956L (no) Fremgangsmate og doseringsformer for kontrollert levering av paliperidon
PL374832A1 (en) Novel substituted benzimidazole dosage forms and method of using same
AU2003297621A8 (en) Medical devices for delivery of therapeutic agents
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
NO20042278D0 (no) Apparat og fremgangsmate for benkirurgi
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
ZA200410229B (en) Administration of therapeutic viruses
EP1372726A4 (en) METHOD FOR REDUCING FAT BY ADMINISTRATING ADIPONECTIN
NO20034097L (no) Hormonerstatningsterapi
HK1066459A1 (en) Pharmaceutical dosage form and method of making
EP1494678A4 (en) hormone therapy PROCEDURE
NO20033123L (no) Terapeutisk hinne dannende sammensetning og behandlingsplan derav
EP1518925A4 (en) GLUCOKINASE PROTEIN CRYSTAL AND METHOD FOR THE DRUG CONSTRUCTION USING THE CRYSTAL
NO20033506L (no) Parasitticidale preparater og metoder for anvendelse
NO20033155D0 (no) Fremgangsmate for hormonerstatningsterapi og dens administreringsform
ITMI20021377A0 (it) Interfaccia ostointegrativa per protesi impiantabili e metodo per il trattamento di detta interfaccia ostointegrativa
IS2331B (is) 2-arýlimínó-2,3-díhýdróþíasólafleiður, aðferðir til að framleiða þær og meðferðarfræðileg notkun þeirra
FR2848817B1 (fr) Matelas therapeutique tricouches pour patients obeses
GB0203518D0 (en) Wager administration system and method of operation thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application